Chronic inflammatory diseases cause a large number of deaths all over the globe. The World Health Organization ranks chronic inflammatory diseases as a major threat to human life. The prevalence of chronic inflammatory diseases is expected to increase persistently for the next thirty years in the U.S. Hence, the rise in chronic inflammatory diseases globally is expected to increase the requirement of research and development activities for exosome therapeutics.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-exosome-therapeutic-market
Data Bridge Market Research analyses a growth rate in the Global Exosome Therapeutics Market is expected to reach USD 1,986.86 thousand by 2030 from USD 550.58 thousand in 2022, growing at a CAGR of 17.40% in the forecast period of 2023 to 2030. Increasing healthcare expenditure will likely to increase the growth of the global exosome therapeutics market.
The rising incidence of oncology diseases is expected to drive the market's growth rate
Oncology has a major impact all over the world. The increase in the incidence of oncology diseases is due to the change in lifestyle and a growth in lifespan. With the natural delivery abilities of exosomes, these have been successfully used as a functional RNA delivery vector and drug for cancer treatment. As cancer incidence is growing across all regions, the usage of exosome therapeutics is also increasing. The exosomes derived from numerous sources encapsulate drugs and deliver therapeutic agents such as small molecule drugs, nucleic acids, and proteins to cancer cells by active or passive targeting. The exosomes would lengthen the half-life of the drug. Thus, the increase in incidences of oncology diseases is likely to drive the market's growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014- 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Natural Exosome, Hybrid Exosome), Source (Mesenchymal Stem Cells, Blood, Body Fluids, Urine, Dendritic Cells, Saliva, Milk, and Others), Therapy (Immunotherapy, Chemotherapy, and Gene Therapy), Transporting Capacity (Bio Macromolecules and Small Molecules), Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Inflammatory Disorders, Organ Transplantation, Gynecology Disorders, Blood Disorders, and Others), Route of Administration (Parenteral and Oral), End User (Research and Academic Institutes, Hospitals, and Diagnostic Centers)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GSK plc. (U.K.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Lily. (U.S.), AstraZeneca (U.S.), Boehringer Ingelheim International GmbH (Germany), CELGENE CORPORATION (U.S.), Sanofi (France), Johnson & Johnson Services, Inc. (U.S.), Dr. Reddy's Laboratories Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), and Bristol-Myers Squibb Company (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The exosome therapeutics market is segmented on the basis of Type, source, therapy, transporting capacity, application, route of administration and end user.
- On the basis of type, the global exosome therapeutics market is segmented into natural exosomes and hybrid exosomes. The natural exosomes segment is expected to dominate the global exosome therapeutics market with a market share of 92.58% because of presence of instrumentation and natural material of the exosomes.
- On the basis of source, the global exosome therapeutics market is segmented into mesenchymal stem cells, blood, body fluids, urine, dendritic cells, saliva milk and others.
The mesenchymal stem cell segment of source segment is anticipated to dominate the exosome therapeutics market
The mesenchymal stem cell segment is expected to dominate the global exosome therapeutics market with a market share of 52.69% due to evolving applications of mesenchymal stem cells and expansion of clinical studies of mesenchymal stem cells based products.
- On the basis of therapy, the global exosome therapeutics market is segmented into immunotherapy, gene therapy and chemotherapy. The immunotherapy segment is expected to dominate the global exosome therapeutics market with a market share of 55.31% owing to the ease of convenience, high precision and development in long tern survival rate.
- On the basis of transporting capacity, the global exosome therapeutics market is segmented into bio macromolecules and small molecules.
The bio macromolecule segment of transporting capacity segment is anticipated to dominate the exosome therapeutics market
The bio macromolecule segment is expected to dominate the global exosome therapeutics market with a market share of 74.18% due to the presence of high sensitivity, ease of availability and increased use of protein therapeutics to cure inflammatory disorders.
- On the basis of application, the global exosome therapeutics market is segmented into metabolic disorders, oncology, cardiac disorders, neurology, inflammatory disorders, organ transplantation, gynecology disorders, blood disorders, and others. The metabolic disorders segment is expected to dominate the global exosome therapeutics market with a market share of 26.16% because of growth in cases of metabolic disorders, increase in demand for one-time therapies and availability of exosome therapeutics or metabolic disorders.
- On the basis of route of administration the global exosome therapeutics market is segmented into parenteral and oral. The parenteral segment is expected to dominate the global exosome therapeutics market with a market share of 97.48% due to rapid onset action and increased bioavailability.
- On the basis of end user, the global exosome therapeutics market is segmented into research and academic institutes, hospitals and diagnostics centers. The research and academic institutes segment is expected to dominate the global exosome therapeutics market with a market share of 72.53% because of growth in research and development of exosomes and support from government in funding exosome therapeutics.
Major Players
Data Bridge Market Research recognizes the following companies as the major exosome therapeutics market players in exosome therapeutics market GSK plc. (U.K.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Lily. (U.S.), AstraZeneca (U.S.), Boehringer Ingelheim International GmbH (Germany).
Market Development
- In 2021, Capricor Therapeutics signed a contract with Johns Hopkins University to increase the exosome platform technology portfolio. This platform technology portfolio would comprise the engineered exosomes for therapeutics and vaccines as part of the company's exosome technology portfolio. This agreement would enable Capricor Therapeutics to engineer exosomes for therapeutics and vaccines.
- In 2020, the Avalon Globocare Corp introduced mesenchymal stromal cell therapeutic platform. Avalon's mesenchymal stromal cell therapeutic platform signifies the culmination of extensive research and development activities and clinical expertise in cellular therapy and stem cell-derived exosome applications.
- In 2020, Exopharm launched the LEAP technology. This technology proved to be an innovation and advancement in exosome therapeutics. This technology aids to purify the extracellular vehicles of exosomes. This technology would also allow the easy scalable production of exosomes.
Regional Analysis
Geographically, the countries covered in the exosome therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in exosome therapeutics market during the forecast period 2023 to 2030
North America dominates the exosome therapeutics market because of the presence of FDA-approved wound debridement devices, the increase in chronic wounds, and the availability of health remuneration policies. Furthermore, the dominance of the natural exosomes segment will further enhance the market growth in this region.
Asia-Pacific is estimated to be the fastest-growing region in exosome therapeutics market the forecast period 2023 to 2030
Asia-Pacific is expected to grow during the forecast period of 2023 to 2030 because of increasing expenditure on healthcare infrastructure and increasing investments for R&D activities in this region. Additionally, growing awareness regarding the treatment of infectious disease cases will further boost the market growth in this region.
For more detailed information about exosome therapeutics market report, click here – https://www.databridgemarketresearch.com/reports/global-exosome-therapeutic-market
